9 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
8
Ending by 2030
May 2027
Next term end
5
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2027 · High confidence
Also notable
Ends Oct 2027 · High confidence
Also notable
Ends May 2027 · High confidence
Monoclonal Antibodies to Programmed Death 1 (PD-1)
US 8,779,105
Cited by 298 later US patents, top 1% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
Human ANTI-B7RP1 Neutralizing Antibodies
US 7,868,140
Renewed at every maintenance window since the 2011 grant; no more fees are due before its term ends in 2027.
Compositions and Methods for Treating Cocaine-Related Disorders
US 10,501,556
Granted 2019. Computed term ends 2027.
Formerly held, still cited
Notable
Ends Oct 2031 · Medium confidence
Granted 2022. Computed term ends 2031.
now held by Bristol-Myers Squibb Company
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 4 terms have ended since Aug 18, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Human Monoclonal Antibodies to Programmed Death 1(PD-1) and Methods for Treating Cancer Using ANTI-PD-1 Antibodies Alone or in Combination with Other Immunotherapeutics | 3 in force | to Dec 2028 |
| Compositions and methods for treating cocaine-related disorders | 2 in force | to Jan 2033 |
| Human ANTI-B7RP1 Neutralizing Antibodies | 2 in force | to Aug 2029 |
| Cation Exchange Chromatography Methods | 1 in force | to Sep 2030 |
| Fully Human Antibodies Specific to CADM1 | 1 in force | to Mar 2030 |
Patents held now
Soonest term end first.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,441,655 | Monoclonal Antibodies to Programmed Death 1 (PD-1) In force · High confidence | In force | High confidence | |
| US 10,501,556 | Compositions and Methods for Treating Cocaine-Related Disorders In force · High confidence | In force | High confidence | |
| US 8,779,105 | Monoclonal Antibodies to Programmed Death 1 (PD-1) In force · High confidence | In force | High confidence | |
| US 7,868,140 | Human ANTI-B7RP1 Neutralizing Antibodies In force · High confidence | In force | High confidence | |
| US 8,008,449 | Human Monoclonal Antibodies to Programmed Death 1(PD-1) and Methods for Treating Cancer Using ANTI-PD-1 Antibodies Alone or in Combination with Other Immunotherapeutics In force · High confidence | In force | High confidence | |
| US 8,981,071 | Human anti-B7RP1 Neutralizing Antibodies In force · High confidence | In force | High confidence | |
| US 8,420,084 | Fully Human Antibodies Specific to CADM1 In force · High confidence | In force | High confidence | |
| US 12,157,757 | Cation Exchange Chromatography Methods In force · Medium confidence | In force | Medium confidence | |
| US 9,758,593 | Compositions and methods for treating cocaine-related disorders In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 9: 2 patents in force now held by others · 45 patents ended · 10 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
5 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed